How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,060 results for

Topical Ointment

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning (...) You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier

2014 Clinical Trials

102. Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning (...) You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier

2014 Clinical Trials

103. A randomized, double-blind, comparative study to assess the safety and efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of secondarily infected traumatic lesions and impetigo due to methicillin-resistant Staphylococcus au (PubMed)

A randomized, double-blind, comparative study to assess the safety and efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of secondarily infected traumatic lesions and impetigo due to methicillin-resistant Staphylococcus au To evaluate the clinical and bacteriological efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of patients with secondarily infected traumatic lesions (SITLs; excluding abscesses) or impetigo due to methicillin (...) -resistant Staphylococcus aureus (MRSA).A randomized, double-blind, double-dummy, multicenter, comparative study (NCT00852540).Patients recruited from 36 study centers in the United States.Patients 2 months or older with SITL (including secondarily infected lacerations or sutured wounds) or impetigo (bullous and nonbullous) suitable for treatment with a topical antibiotic, with a total Skin Infection Rating Scale score of 8 or greater, including a pus/exudate score of 3 or greater.Patients received

2014 Advances in skin & wound care Controlled trial quality: predicted high

104. Combination treatment of oral terbinafine with topical terbinafine and 10% urea ointment in hyperkeratotic type tinea pedis. (PubMed)

Combination treatment of oral terbinafine with topical terbinafine and 10% urea ointment in hyperkeratotic type tinea pedis. Hyperkeratotic-type tinea pedis is chronic and recalcitrant to topical antifungal agents. Some topical antifungal agents are effective; however, long duration of therapy is required, which often reduce the treatment compliance of patients. To seek for short period therapy of hyperkeratotic type tinea pedis, in this study, we observed the efficacy and safety of treatment (...) of topical terbinafine and 10% urea ointment combined oral terbinafine. Participants with hyperkeratotic type tinea pedis were randomly assigned to two groups. Patients in group I were treated with oral terbinafine for 2 weeks and topical terbinafine and 10% urea ointment for 4 weeks, whereas in group II, only the above topical agents were applied for 12 weeks. Clinical improvement rates and fungal eradication rates were compared between the two groups at 24 weeks after the initiation of treatment

2014 Mycoses Controlled trial quality: uncertain

105. Internal sphincterotomy versus topical nitroglycerin ointment for chronic anal fissure. (PubMed)

Internal sphincterotomy versus topical nitroglycerin ointment for chronic anal fissure. Anal fissure is a common benign condition. An anorectal problem is defined as a split in the anal canal mucosa that extends from the dentate line to the anal verge. Chronic anal fissure is defined by a history of symptoms present for more than 2 months' duration and with a triad of external skin tags, namely, a hypertrophied anal papilla, an ulcer with rolled edges, and a base exposing the internal sphincter (...) . Because complications such as incontinence are associated with surgical treatment, chemical sphincterotomy is currently favored.The objective of this study is to compare the difference in outcome between open partial lateral anal sphincterotomy and application of topical 0.2% nitroglycerin ointment for the treatment of chronic anal fissure.This was a quasi-experimental study carried out between January 16, 2007 and January 15, 2008 in the Surgical Department of Jinnah Hospital, Lahore, Pakistan. Sixty

Full Text available with Trip Pro

2014 Asian journal of surgery / Asian Surgical Association Controlled trial quality: uncertain

106. Nursing preference of topical silver sulfadiazine versus collagenase ointment for treatment of partial thickness burns in children: survey follow-up of a prospective randomized trial. (PubMed)

Nursing preference of topical silver sulfadiazine versus collagenase ointment for treatment of partial thickness burns in children: survey follow-up of a prospective randomized trial. We performed a nursing survey to inquire about nursing preferences toward the use of silver sulfadiazine (SSD) and collagenase (CO). We performed a survey between September 2012 and December 2012 asking nurses to rate the application/removal of both products and provide a description of their preferences. Ten

2014 Journal of trauma nursing : the official journal of the Society of Trauma Nurses Controlled trial quality: uncertain

107. An investigator-initiated, double-blind, vehicle-controlled pilot study: Assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis. (PubMed)

An investigator-initiated, double-blind, vehicle-controlled pilot study: Assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis. Topical corticosteroids are the most common first-line treatment for psoriasis. Tachyphylaxis, a decreased response to treatment with repetitive application of the drug, is a controversial phenomenon associated with topical corticosteroid treatment.We sought to prove or disprove tachyphylaxis to occluded halobetasol (...) to recurrence (P=.92) of the treated plaques was found between phases 1 and 2A. Percentage of improvement was higher in phase 2A compared with phase 1 (89.4%, P<.05 vs 71%, P<.05), as a result of reduction of vehicle effect. In phase 2B, a greater improvement was found for previously corticosteroid-treated plaques.Limitations are small sample size and 1 corticosteroid tested.No evidence of tachyphylaxis to the topical corticosteroid halobetasol 0.05% ointment treatment in patients with plaque psoriasis

2014 Journal of American Academy of Dermatology Controlled trial quality: uncertain

108. The Effect Of Topical Ointment On Neonatal Sepsis In Preterm Infants. (PubMed)

The Effect Of Topical Ointment On Neonatal Sepsis In Preterm Infants. To investigate the effects of topical ointment therapy on neonatal sepsis in premature infants.A total of 197 premature infants≤34 weeks gestation were randomized to receive topical ointment (Aquaphor Original Emollient) or routine skin care group. Skin cultures were obtained on 3th, 7th and 14th day and blood cultures were obtained if sepsis was suspected clinically. Data included the maternal and neonatal characteristics (...) and necrotizing enterocolitis between the groups. Although the rate of death was higher in the topical ointment group, no statistically significant difference was found between the groups.Our data suggests that applying topical ointment during the first 2 postnatal weeks did not affect the risk of neonatal sepsis in preterm infants, although it changed the bacterial flora on the skin compare to the routine care group.

2014 The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians Controlled trial quality: uncertain

109. The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial

The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial The safety and scientific validity of this study

2013 Clinical Trials

110. The safety and efficacy of topical retapamulin ointment versus placebo ointment in the treatment of secondarily infected traumatic lesions: a randomized, double-blind superiority study. (PubMed)

The safety and efficacy of topical retapamulin ointment versus placebo ointment in the treatment of secondarily infected traumatic lesions: a randomized, double-blind superiority study. To evaluate whether retapamulin 1% is clinically superior to a placebo in the treatment of patients with secondarily infected traumatic lesions.The study was a double-blind, placebo-controlled, parallel-group, phase 3 study.Patients were recruited from 5 countries.The aforementioned patients were all 2 months

2013 Advances in skin & wound care Controlled trial quality: predicted high

111. Re-Use of Open tubes of Antibiotic Creams and Ointments: Clinical Evidence, Safety, and Guidelines

Re-Use of Open tubes of Antibiotic Creams and Ointments: Clinical Evidence, Safety, and Guidelines Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid (...) Creams and Ointments: Clinical Evidence, Safety, and Guidelines DATE: 03 July 2012 RESEARCH QUESTIONS 1. What is the clinical evidence regarding the safety of the use of open tubes of antibiotic creams and ointments for wound care for patients in hospitals or long term care? 2. What are the evidence-based guidelines regarding the use of open tubes of antibiotic creams and ointments for wound care for patients in hospitals or long term care? KEY MESSAGE No literature was identified regarding

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

112. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (UK National Health Servi

assessment for children. Measure of benefit: The measure of benefit was quality-adjusted life-years (QALYs). Cost data: The direct medical costs included the tacrolimus ointment, consultant dermatology and out-patient visits, phototherapy, topical steroids, oral medications, and in-patient stays. Published sources were used to measure and value these resources. These included MIMS 2009, NHS National Reference Costs, and the Personal Social Services Research Unit 2008. The costs of discontinuing (...) simulations at the acceptability threshold of £30,000 per QALY. Authors' conclusions The authors concluded that maintenance therapy, using tacrolimus ointment, for children and adults with moderate or severe atopic dermatitis, produced additional health benefits, at lower costs, and was cost-effective, compared with reactive treatment. CRD commentary Interventions: The two strategies were well described. It was unclear why topical corticosteroids and topical calcineurin inhibitors were not analysed, given

2011 NHS Economic Evaluation Database.

113. Topical steroids better than vitamin D for treating scalp psoriasis

, but the difference was not considered clinically important. The combination ointment costs almost £20 for 30g compared to a 30g tube of typical steroid ointment which costs about £4. Scalp psoriasis is a common condition that can be itchy and embarrassing for many. A variety of topical lotions, solutions or gels are available to treat the condition, so this review of published research aimed to help doctors and patients find out which was the most effective and safest option. This systematic review found 59 (...) . In extreme cases it can cause hair loss, although this is usually only temporary. Topical treatments (creams and ointments for the skin) such as corticosteroids (steroids) and vitamin D are usually the first treatments tried, but applying them to the scalp is difficult because of hair on the head. It is also not clear which works best. This study aimed to help doctors and patients decide which of the wide variety of topical treatments available work best, and the type and frequency of any side effects

2018 NIHR Dissemination Centre

114. Insect Bites - Guidelines for Prescribing Topical Hydrocortisone

that topically applied vinegar to neutralize wasp stings will be effective as the venom spreads deep into tissues within a few minutes. Prescription drug option Hydrocortisone 1% cream, lotion or ointment is indicated for topical therapy where anti-inflammatory, anti-allergic and anti-pruritic activity is required. Hydrocortisone 1% is considered a mild corticosteroid. Note: Hydrocortisone 1% is Schedule 1 (Rx) only for patients under 2. Otherwise, it is an OTC product that is not eligible for the minor (...) their application. If a reaction to a repellent is suspected, wash off, seek medical attention and take container with you. HYDROCORTISONE (< 2 years of age) 1% TOPICAL CREAM 1% TOPICAL OINTMENT 1% TOPICAL LOTION pseudoDIN: 00951089 Max of 8 claims per 365 days per patient May prescribe sufficient quantity to treat up to 7 days, no refills. For help prescribing the proper quantity of topicals using finger-tip units, see: C-Health - (Free access) Saskatchewan HealthLine online - (Free access) Canadian

2016 medSask

115. Efficacy of topical alpha ointment (containing natural henna) compared to topical hydrocortisone (1%) in the healing of radiation-induced dermatitis in patients with breast cancer: a randomized controlled clinical trial. (PubMed)

Efficacy of topical alpha ointment (containing natural henna) compared to topical hydrocortisone (1%) in the healing of radiation-induced dermatitis in patients with breast cancer: a randomized controlled clinical trial. This two-arm, randomized clinical study aimed to compare efficacy between topical Alpha ointment and topical hydrocortisone cream (1%) in the healing of radiation-induced dermatitis in breast cancer patients.The inclusion criteria comprised newly pathologically proven, locally (...) advanced breast cancer (treated with modified radical mastectomy followed by sequential adjuvant treatments, including chest wall radiotherapy [45-50.4 Gy]) and grade 2 and/or 3 chest wall dermatitis. The exclusion criteria were comprised of any underlying disease or medications interfering with the wound healing process, previous history of chest wall radiotherapy, and concurrent use of chemotherapy. Sixty eligible patients were randomly assigned to use either topical Alpha ointment (study arm, n=30

Full Text available with Trip Pro

2013 Iranian journal of medical sciences Controlled trial quality: uncertain

116. Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis

Completion Date : June 2017 Actual Study Completion Date : June 2017 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: 0.3% OPA-15406 Ointments Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily. Drug: OPA-15406 Experimental: 1% OPA-15406 Ointments Subjects were treated with assigned 1% OPA-15406 ointment twice daily. Drug: OPA-15406 Placebo Comparator: Placebo Ointments (...) Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2017 Clinical Trials

117. Study of SOR007 Ointment for Actinic Keratosis

Phase 2 Detailed Description: In this Phase 2, randomized, double-blind, dose rising trial, subjects with actinic keratosis will receive topical application of SOR007 Ointment (in four concentrations) or SOR007 Ointment vehicle to the face twice daily for up to 28 days. Subjects will be enrolled in four dose-escalating cohorts of eight subjects and randomized to SOR0007 or Ointment vehicle in a ratio of 3:1. Cohorts will be enrolled sequentially starting at the lowest concentration. Safety (...) links provided by the National Library of Medicine resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: SOR007 0.15% SOR007 Ointment 0.15% applied to the face twice daily for 28 days Drug: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU

2017 Clinical Trials

118. A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK004)

Ointment 1% Drug: Placebo Phase 3 Detailed Description: This study will be a double-blinded, multicenter, activity, and safety study of KX2-391 Ointment administered topically to the face or scalp of subjects with actinic keratosis. The study consists of Screening, Treatment, Follow-up, and Recurrence Follow-up Periods. Eligible subjects will receive X consecutive days of topical treatment, to be applied at the study site. Activity (lesion counts) and safety evaluations will be performed. Study Design (...) A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK004) A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK004) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

119. A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

Phase 3 Detailed Description: This study will be a double-blinded, multicenter, activity, and safety study of KX2-391 Ointment administered topically to the face or scalp of subjects with actinic keratosis. The study consists of Screening, Treatment, Follow-up, and Recurrence Follow-up Periods. Eligible subjects will receive X consecutive days of topical treatment, to be applied at the study site. Activity (lesion counts) and safety evaluations will be performed. Study Design Go to Layout table (...) A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2017 Clinical Trials

120. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. (PubMed)

Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. Long-term topical treatment is often required for atopic dermatitis (AD), a chronic inflammatory skin disease.To assess the long-term safety results from a multicenter, open-label, 48-week safety study (AD-303) of patients (N = 517) ≥2 years of age with mild to moderate AD who continued crisaborole treatment, a topical phosphodiesterase-4 inhibitor, after completing a 28-day phase 3 (...) of TEAEs were consistent. The most frequently reported treatment-related AEs (overall, 10.2%) were dermatitis atopic (3.1%), application-site pain (2.3%), and application-site infection (1.2%). Nine patients (1.7%) discontinued the long-term study because of TEAEs.Long-term efficacy was not analyzed.Crisaborole ointment had a low frequency of treatment-related AEs over 48 weeks of treatment of patients with AD.Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights

Full Text available with Trip Pro

2017 Journal of American Academy of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>